Vertiflex®, Inc. Announces Submission of Final PMA Module to the FDA, for the Superion® Interspinous Spacer System
April 1, 2014
SAN CLEMENTE, CA (April 1, 2014) – Vertiflex®, Inc., a leading innovator of advanced minimally invasive spinal surgery technologies, announces submission of the final module of the pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) to support approval for the Superion® Interspinous Spacer System. The final module covers the clinical results from the Superion IDE trial evaluating the safety and effectiveness of the Superion Interspinous Spacer (Superion ISS) for the treatment of lumbar spinal stenosis.
“This submission is the culmination of several years of dedicated research,” commented Earl R. Fender, President and Chief Executive Officer of Vertiflex, Inc. “This is the largest and most rigorous FDA trial ever completed for spinal stenosis. I am very grateful for the dedication of our research team and look forward to working with the FDA to bring this promising technology to market, to help many of the more than 1 million U.S. patients diagnosed annually, with lumbar spinal stenosis.”
The Superion IDE trial involved enrollment of 470 patients between June 2008 and December 2012 at 31 centers across the United States. Patients were randomized 1:1 to either the Superion ISS or the commercially available X-STOP® IPD®. Superion is designed to achieve indirect spinal decompression for patients suffering from Neurogenic Intermittent Claudication due to moderate lumbar spinal stenosis. Superion is implanted minimally invasively through a cannula designed to be less traumatic to the patient. The Superion ISS can be implanted under general or local anesthesia.
About Vertiflex, Inc.
Vertiflex is a privately held medical device company dedicated to the advancement of minimally invasive solutions for the treatment of lumbar spinal stenosis, which is the leading cause of spinal surgery in the elderly. Founded in 2005 and headquartered in San Clemente, CA, Vertiflex has developed proprietary, minimally invasive technologies for performing both indirect and direct decompressions of the lumbar spine. These procedures fill the gap in the stenosis treatment continuum between conservative care and traditional spine surgery, providing new options for interventional spine physicians and less invasive options for traditional spine surgeons. To date, Vertiflex has compiled the largest, most rigorous, body of device clinical evidence, related to lumbar spinal stenosis.